Michael H. Court, B.V.Sc., Ph.D.,
Diplomate, American College of Veterinary Anesthesiologists
Professor and William R. Jones Endowed Chair
michael.court@vetmed.wsu.edu
Education
B.V.Sc. Hons., Queensland University (1981)
Internship - Small Animal, University of Sydney (1982)
Residency - Anesthesia, Tufts University (1985)
Fellowship - Pharmacology, Flinders University (1999)
Ph.D. - Pharmacology and Experimental Therapeutics, Tufts University (2000)
Research Interests
My laboratory primarily conducts pharmacogenomic research, including
studies designed to identify genetic variants and related mechanisms that
determine interindividual differences in drug effect (both beneficial and
adverse). The long-term goal of our work is to translate these findings
into clinical practice and improve the treatment of important diseases
through pharmacogenomic-guided selection of the most effective and safest
drug and drug dose for the individual patient (individualized therapeutics).
One of the main projects in our laboratory is attempting to understand the
molecular and genetic basis for increased sensitivity of some sighthound dog
breeds (such as greyhounds) to certain injectable anesthetic agents.
Another major project involves identifying and characterizing microRNAs that
determine interindividual variability in drug glucuronidation in human
liver.
Publications
Shrestha B, Reed JM, Starks PT, Kaufman GE, Goldstone JV, Roelke ME,
O'Brien SJ, Koepfli KP, Frank LG, Court MH. Evolution of a major drug
metabolizing enzyme defect in the domestic cat and other felidae:
Phylogenetic timing and the role of hypercarnivory. PLoS One. 2011 Mar
28;6(3):e18046.
Kwara A, Lartey M, Sagoe KW, Court MH. Paradoxically elevated efavirenz
concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT
genotype on rifampin-containing antituberculous therapy. AIDS. 2011 Jan
28;25(3):388-90.
Mosher CM, Court MH. Comparative and veterinary pharmacogenomics. Handb
Exp Pharmacol. 2010;199:49-77.
Oleson L, von Moltke LL, Greenblatt DJ, Court MH. Identification of
polymorphisms in the 3'-untranslated region of the human pregnane X receptor
(PXR) gene associated with variability in cytochrome P450 3A (CYP3A)
metabolism. Xenobiotica. 2010 Feb;40(2):146-62.
He X, Hesse LM, Hazarika S, Masse G, Harmatz JS, Greenblatt DJ, Court MH.
Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is
reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion.
Br J Clin Pharmacol. 2009 Nov;68(5):721-30.
Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7
genetic polymorphisms are predictors of efavirenz mid-dose concentration in
HIV-infected patients. AIDS. 2009 Oct 23;23(16):2101-6.
Kwara A, Lartey M, Boamah I, Rezk NL, Oliver-Commey J, Kenu E, Kashuba
AD, Court MH. Interindividual Variability in Pharmacokinetics of Generic
Nucleoside Reverse Transcriptase Inhibitors in TB/HIV-Coinfected Ghanaian
Patients: UGT2B7*1c Is Associated With Faster Zidovudine Clearance and
Glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. CYP2B6 (c.516G>T) and
CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of
efavirenz plasma concentrations in HIV-infected patients. Br J Clin
Pharmacol. 2009 Apr;67(4):427-36.
Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt
DJ, Court MH: UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: 1.
Identification of polymorphisms in the 5’-regulatory and exon 1 regions, and
association with human liver UGT1A6 gene expression and glucuronidation. J
Pharmacol Exp Ther. 2005 Mar; 313(3):1331-1339.
Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt
DJ, Court MH: UDP-glucuronosyltransferase (UGT) 1A6 pharmacogenetics: 2.
Structure-function studies of recombinant UGT1A6 amino acid variants. J
Pharmacol Exp Ther. 2005 Mar; 313(3):1340-1346.
Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, Von Moltke
LL, Greenblatt DJ: UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics:
UGT2B15 D85Y genotype and gender are major determinants of oxazepam
glucuronidation by human liver. J Pharmacol Exp Ther. 2004
Aug;310(2):656-65.
Hay Kraus BL, Greenblatt DJ, Venkatakrishnan K, Court MH: Evidence
for propofol hydroxylation by cytochrome P450 2B11 in canine liver
microsomes: Dog breed and gender differences. Xenobiotica
30(6):575-588, 2000.
Court MH and Greenblatt DJ: Molecular genetic basis for deficient
glucuronidation of acetaminophen in cats: UGT1A6 is a pseudogene, and
evidence for reduced diversity of expressed hepatic UGT1A isoforms
Pharmacogenetics 10:355-369, 2000.
Court MH, Hay Kraus BL, Hill DW, Kind AJ and Greenblatt DJ:
Propofol hydroxylation by dog liver microsomes: Assay development and dog
breed differences. Drug Metabolism and Disposition 27(11):1293-1299, 1999.
Court MH: Anesthesia of the sighthound. Clinical Techniques in
Small Animal Practice 14(1): 38-43, 1999.
